No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 33% Share Price Bounce
TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025
Needham Reiterates Hold on TransMedics Groupto Hold
TransMedics Group Analyst Ratings
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120
TransMedics Group's OCS Drives Structural Transformation in Liver Transplantation With Increased DCD Liver Utilization